Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
143
NCT02978755
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 30, 2016
Completion: Jun 10, 2020
NCT03799731
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Phase: Phase 2
Start: Jul 11, 2018
Completion: Feb 10, 2021